New Radiopharmaceutical Therapy Accreditation Program Announced by SNMMI and IAC
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Intersocietal Accreditation Commission (IAC) have announced an enhanced partnership that will help ensure quality care for patients receiving radiopharmaceutical therapy. The partnership includes a new Radiopharmaceutical Therapy accreditation program that will provide facilities with a mechanism for demonstrating their commitment to quality and patient safety in radiopharmaceutical therapy.
The new Radiopharmaceutical Therapy accreditation program augments the existing IAC accreditation areas of Nuclear Cardiology, General Nuclear Medicine and Positron Emission Tomography (PET).
“Radiopharmaceutical therapy is a powerful technique for treating cancer that is now being used to great benefit in patients with prostate and other cancers. It is essential that patients receiving radiopharmaceutical therapy be confident that their providers meet high standards of training and experience. The new SNMMI-IAC Radiopharmaceutical Therapy accreditation helps assure that sites delivering radiopharmaceutical therapy are qualified and experienced, have appropriate facilities and equipment, and can offer safe and reliable radiopharmaceutical therapy,” said Richard L. Wahl, MD, SNMMI Immediate Past President and IAC Nuclear/PET Board member.
“IAC and SNMMI have worked together for many years, as SNMMI is a founding sponsoring organization of the IAC Nuclear/PET accreditation program. The creation of the new Radiopharmaceutical Therapy accreditation offering is possible through our collaboration and leverages both organizations’ strengths toward our aligned missions focused on quality and safe patient care. Through a multi-specialty approach, the SNMMI representatives along with our other sponsoring organizations, have contributed greatly to the development of standards for radiopharmaceutical therapy, ensuring that they are reflective of SNMMI guidelines and current best practices that lead to improved patient care,” said Howard Lewin, MD, FACC, FASNC, President of the IAC Nuclear/PET Board of Directors.
“SNMMI is excited about this accreditation program because it builds upon both the SNMMI Radiopharmaceutical Therapy Centers of Excellence and the IAC nuclear medicine accreditation programs,” said SNMMI President Munir Ghesani, MD, FACNM, FACR.
Facilities interested in receiving information about the new program are encouraged to visit intersocietal.org/programs/nuclear-pet to complete an interest form for the Radiopharmaceutical Therapy program.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval